Skip to main content

MDL Status for 16 Opioid Lawsuits from Texas Counties

MDL Status for 16 Opioid Lawsuits from Texas Counties

MDL Status for 16 Opioid Lawsuits from Texas Counties

Introduction

The Texas JPML on Wednesday granted consolidation request for 16 opioid lawsuits by the defendants Purdue Pharma, McKesson Corp. and other opioid makers and distributors from Texas counties.

Considering the common ground for all these cases, the panel decided that a single pretrial judge should take charge of these 16 cases and any tag-along cases that may follow against all defendants.

More than 400 opioid-related lawsuits are centralized as a part of a multidistrict litigation, MDL No. 2804 (In Re: National Prescription Opiate Litigation) in the Northern District of Ohio before U.S. District Judge Dan A. Polster. The first state court trial against Opioid Big Pharma industry and its affiliates is slated to begin in May 2019 in Oklahoma.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest News

title demo for news

Categories: Settlements

created dropdown in quarterly-results page in localy, and explore all the component codes 

Zantac Settles 4,000 Lawsuits in U.S. Courts

Categories: General

Sanofi has announced a settlement agreement regarding approximately 4,000 Zantac cancer lawsuits filed in state courts across the country.

Valsartan Recall Lawsuit Set for Trial

Categories: General

Years after the initiation of Valsartan recalls, the U.S. District Judge overseeing lawsuits filed by individuals harmed by tainted versions of…

Our Legal Drafting Services    
start @ $25 per hour.